Amgen: Good News Comes in Twos

Nomura’s M. Ian Somaiya and Matthew Luchini consider the impact of two pieces of good news on Amgen’s (AMGN) stock: Associated Press Combination of positive Romosozumab data in postmenopausal osteoporosis and neuroscience partnership with Novartis provided much needed visibility on long-term revenue growth. The collaboration gives Amgen access to Novartis’ (NVS) CNP520, which is currently in Phase […]